Pfizer Licenses Chai AI Platform for Drug Discovery
Chai Discovery has entered into a licensing agreement with pharmaceutical giant Pfizer, marking a significant step in the growing adoption of artificial intelligence technologies across the drug discovery industry. The partnership will give Pfizer access to Chai’s advanced AI-powered molecular design platform, including early use of the company’s next-generation Chai-3 model and a customized version tailored to Pfizer’s proprietary data and research workflows.
The agreement underscores the pharmaceutical sector’s increasing reliance on artificial intelligence to accelerate the development of new medicines and improve the efficiency of early-stage research. By integrating Chai’s technology into its drug discovery engine, Pfizer aims to enhance its ability to identify and design promising therapeutic candidates, particularly in areas where traditional methods have faced challenges.
Chai Discovery specializes in developing generative AI models capable of predicting and engineering molecular interactions. The company’s technology is designed to help scientists create new biomolecules with specific functional properties, potentially reducing the time and resources required to discover novel treatments.
Drug discovery has historically been a lengthy and costly process involving repeated rounds of laboratory testing and optimization. Researchers often spend years evaluating thousands of molecular candidates before identifying a viable therapeutic lead. Chai believes its AI-driven platform can dramatically shorten these timelines by designing biomolecules from scratch and predicting their performance before they are synthesized and tested in the laboratory.
Joshua Meier, co-founder of Chai Discovery, said the collaboration represents an opportunity to combine the company’s frontier AI technology with Pfizer’s extensive scientific expertise and data resources. He noted that the partnership could help accelerate biologics discovery and enable the pursuit of difficult therapeutic targets that have proven challenging using conventional drug development approaches.
A key component of the agreement is Pfizer’s access to Chai-3, the company’s previously undisclosed AI model. According to Chai, the new platform delivers significant improvements in AI-driven antibody design, including a doubling of the success rate achieved by its predecessor. The model is designed to generate antibodies that meet therapeutic standards while improving capabilities in areas such as multispecific molecules, binding to difficult-to-target proteins, and broader generalization across different biological applications.
The launch of Chai-3 builds on the company’s earlier Chai-2 platform, released in 2025. Chai-2 was described as the first zero-shot antibody design system capable of achieving double-digit experimental hit rates while producing molecules with drug-like properties. The company reported that the technology represented a major advancement over previous computational methods and enabled discovery timelines to be reduced from months to weeks.
For Pfizer, the agreement provides access to cutting-edge AI tools that may enhance productivity and increase the likelihood of identifying successful biologic therapies. The company will also leverage a custom AI model trained using its proprietary datasets, allowing the platform to be optimized for Pfizer’s specific research objectives and development processes.
The partnership reflects a broader industry trend in which pharmaceutical companies are moving beyond experimental AI initiatives and incorporating advanced machine learning technologies directly into their core research operations. As AI-generated drug candidates continue to demonstrate promising results, collaborations such as the one between Chai Discovery and Pfizer are expected to play an increasingly important role in shaping the future of pharmaceutical innovation.